Peptide-based probes for targeted molecular imaging.
暂无分享,去创建一个
Seulki Lee | Xiaoyuan Chen | Jin Xie | Seulki Lee | Xiaoyuan Chen | J. Xie | Jin Xie
[1] Anastasia Nikolopoulou,et al. Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting , 2008, Journal of Nuclear Medicine.
[2] Klemens Scheidhauer,et al. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] Ettore Benedetti,et al. Criteria for the Design and Biological Characterization of Radiolabeled Peptide-Based Pharmaceuticals , 2012, BioDrugs.
[4] Sanjiv S Gambhir,et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. , 2006, Nano letters.
[5] J. Reubi,et al. NPY receptors in human cancer: A review of current knowledge , 2007, Peptides.
[6] Matthias Friebe,et al. Novel chemically modified analogues of neuropeptide Y for tumor targeting. , 2008, Bioconjugate chemistry.
[7] J. Reubi,et al. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[8] Weibo Cai,et al. Are quantum dots ready for in vivo imaging in human subjects? , 2007, Nanoscale research letters.
[9] Franz Buchegger,et al. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] Raoul Kopelman,et al. Vascular Targeted Nanoparticles for Imaging and Treatment of Brain Tumors , 2006, Clinical Cancer Research.
[11] Tomohiko Mori,et al. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. , 2006, Nuclear medicine and biology.
[12] Jean-Pierre Vincent,et al. Neurotensin receptors: Binding properties, transduction pathways, and structure , 1995, Cellular and Molecular Neurobiology.
[13] Fan Wang,et al. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. , 2009, Journal of medicinal chemistry.
[14] Abass Alavi,et al. PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] Vasilis Ntziachristos,et al. Inflammation in Atherosclerosis: Visualizing Matrix Metalloproteinase Action in Macrophages In Vivo , 2006, Circulation.
[16] R. Moats,et al. In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts , 2004, Cancer Research.
[17] Fan Wang,et al. 68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin αvβ3 PET imaging , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[18] Chenjie Xu,et al. PET/MRI Dual-Modality Tumor Imaging Using Arginine-Glycine-Aspartic (RGD)–Conjugated Radiolabeled Iron Oxide Nanoparticles , 2008, Journal of Nuclear Medicine.
[19] Georges von Degenfeld,et al. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. , 2007, Nature chemical biology.
[20] D. Edwards,et al. Cancer: Proteases — invasion and more , 1998, Nature.
[21] Philippe Robert,et al. Recent advances in iron oxide nanocrystal technology for medical imaging. , 2006, Advanced drug delivery reviews.
[22] Subhani M Okarvi,et al. Peptide‐based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases , 2004, Medicinal research reviews.
[23] S. Nie,et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy , 2008 .
[24] Tamitake Itoh,et al. Semiconductor quantum dots and metal nanoparticles: syntheses, optical properties, and biological applications , 2008, Analytical and bioanalytical chemistry.
[25] Richard P Baum,et al. Imaging of neuroendocrine tumors. , 2006, Seminars in nuclear medicine.
[26] David Piwnica-Worms,et al. Single-cell imaging of retinal ganglion cell apoptosis with a cell-penetrating, activatable peptide probe in an in vivo glaucoma model , 2009, Proceedings of the National Academy of Sciences.
[27] Igor L. Medintz,et al. Quantum dot bioconjugates for imaging, labelling and sensing , 2005, Nature materials.
[28] Weibo Cai,et al. Imaging of integrins as biomarkers for tumor angiogenesis. , 2008, Current pharmaceutical design.
[29] C Susini,et al. Rationale for the use of somatostatin analogs as antitumor agents. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] J. Reubi,et al. High Expression of Neuropeptide Y1 Receptors in Ewing Sarcoma Tumors , 2008, Clinical Cancer Research.
[31] L. Brand,et al. Resonance energy transfer: methods and applications. , 1994, Analytical biochemistry.
[32] R. Weissleder,et al. Fluorescence molecular tomography resolves protease activity in vivo , 2002, Nature Medicine.
[33] Vasilis Ntziachristos,et al. Shedding light onto live molecular targets , 2003, Nature Medicine.
[34] Emanuel Christ,et al. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. , 2008, The New England journal of medicine.
[35] G. Morelli,et al. Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy. , 2004, Current pharmaceutical design.
[36] H. Dai,et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. , 2020, Nature nanotechnology.
[37] Eun Kyoung Ryu,et al. 18F-Labeled BBN-RGD Heterodimer for Prostate Cancer Imaging , 2008, Journal of Nuclear Medicine.
[38] S. Gambhir,et al. Noninvasive Raman spectroscopy in living mice for evaluation of tumor targeting with carbon nanotubes. , 2008, Nano letters.
[39] Martin Gotthardt,et al. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[40] M A Horton,et al. The alpha v beta 3 integrin "vitronectin receptor". , 1997, The international journal of biochemistry & cell biology.
[41] J. Reubi,et al. GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting , 2007, Journal of Nuclear Medicine.
[42] Sol Kimel,et al. Targeting small-cell lung cancer with novel fluorescent analogs of somatostatin. , 2005, Lung cancer.
[43] Ick Chan Kwon,et al. Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[44] M. Walter,et al. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[45] Ralph Weissleder,et al. In vivo imaging of molecularly targeted phage. , 2006, Neoplasia.
[46] E. Krenning,et al. Somatostatin receptor imaging. , 2002, Seminars in nuclear medicine.
[47] Ralph Weissleder,et al. In vivo molecular target assessment of matrix metalloproteinase inhibition , 2001, Nature Medicine.
[48] J. Frangioni. In vivo near-infrared fluorescence imaging. , 2003, Current opinion in chemical biology.
[49] E Helene Sage,et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. , 2003, Cancer research.
[50] M. Atkins,et al. Interaction of an alpha-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases. , 1992, Cancer research.
[51] Wole Soboyejo,et al. LHRH-conjugated Magnetic Iron Oxide Nanoparticles for Detection of Breast Cancer Metastases , 2006, Breast Cancer Research and Treatment.
[52] Yubin Miao,et al. Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging. , 2007, Frontiers in bioscience : a journal and virtual library.
[53] S. Schulz,et al. New Pansomatostatin Ligands and Their Chelated Versions: Affinity Profile, Agonist Activity, Internalization, and Tumor Targeting , 2008, Clinical Cancer Research.
[54] Thangavel Arunachalam,et al. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[55] Ralph Weissleder,et al. Nanoparticle imaging of integrins on tumor cells. , 2006, Neoplasia.
[56] Weibo Cai,et al. Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging , 2008, Nature Protocols.
[57] David Piwnica-Worms,et al. An improved cell-penetrating, caspase-activatable, near-infrared fluorescent peptide for apoptosis imaging. , 2009, Bioconjugate chemistry.
[58] Alain Blanc,et al. Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[59] Kinneret Keren,et al. Dynamic imaging of protease activity with fluorescently quenched activity-based probes , 2005, Nature chemical biology.
[60] Ick Chan Kwon,et al. Activatable imaging probes with amplified fluorescent signals. , 2008, Chemical communications.
[61] Eduard Schreibmann,et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[62] Byung-Heon Lee,et al. Phage display selection of peptides that home to atherosclerotic plaques: IL-4 receptor as a candidate target in atherosclerosis , 2008, Journal of cellular and molecular medicine.
[63] Sol Kimel,et al. Diagnostic targeting of colon cancer using a novel fluorescent somatostatin conjugate in a mouse xenograft model , 2008, International journal of cancer.
[64] Vasilis Ntziachristos,et al. Looking and listening to light: the evolution of whole-body photonic imaging , 2005, Nature Biotechnology.
[65] W. Semmler,et al. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands , 2001, Nature Biotechnology.
[66] J. Reubi,et al. Peptide-Based Probes for Cancer Imaging , 2008, Journal of Nuclear Medicine.
[67] S. Gambhir,et al. Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics , 2005, Science.
[68] Martin A Walter,et al. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[69] C. Tung,et al. Fluorescent peptide probes for in vivo diagnostic imaging , 2004, Biopolymers.
[70] Ajay Kumar Gupta,et al. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. , 2005, Biomaterials.
[71] J. Matthew Mauro,et al. Long-term multiple color imaging of live cells using quantum dot bioconjugates , 2003, Nature Biotechnology.
[72] S. Korsmeyer,et al. Cell Death in Development , 1999, Cell.
[73] Peter Hohenberger,et al. 68Ga-Labeled Bombesin Studies in Patients with Gastrointestinal Stromal Tumors: Comparison with 18F-FDG , 2007, Journal of Nuclear Medicine.
[74] Horst Kessler,et al. First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography , 2004, Clinical Cancer Research.
[75] Ping Yu,et al. In Vitro and In Vivo Evaluation of Alexa Fluor 680-Bombesin[7–14]NH2 Peptide Conjugate, a High-Affinity Fluorescent Probe with High Selectivity for the Gastrin-Releasing Peptide Receptor , 2007, Molecular imaging.
[76] Chenjie Xu,et al. Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. , 2008, Journal of the American Chemical Society.
[77] J. Reubi. Peptide receptors as molecular targets for cancer diagnosis and therapy. , 2003, Endocrine reviews.
[78] Jean E Rivier,et al. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. , 2008, Journal of medicinal chemistry.
[79] T J Hoffman,et al. Evaluation of an (111)In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[80] Harald Sontheimer,et al. Chlorotoxin Inhibits Glioma Cell Invasion via Matrix Metalloproteinase-2* , 2003, The Journal of Biological Chemistry.
[81] Christopher H Contag,et al. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. , 2008, Nature medicine.
[82] M. Cybulsky,et al. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. , 1991, Science.
[83] J. Reubi,et al. Targeting CCK receptors in human cancers. , 2007, Current topics in medicinal chemistry.
[84] A. Cuthbertson,et al. NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. , 2006, Bioorganic & medicinal chemistry letters.
[85] Wolfhard Semmler,et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. , 2007, Cancer research.
[86] Weibo Cai,et al. Near-Infrared Fluorescence Imaging of Tumor Integrin αvβ3 Expression with Cy7-Labeled RGD Multimers , 2006, Molecular Imaging and Biology.
[87] Chad A Mirkin,et al. Nanostructures in biodiagnostics. , 2005, Chemical reviews.
[88] Sanjiv S. Gambhir,et al. Dual-Function Probe for PET and Near-Infrared Fluorescence Imaging of Tumor Vasculature , 2007, Journal of Nuclear Medicine.
[89] Judit Erchegyi,et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors , 2006, Proceedings of the National Academy of Sciences.
[90] Young-Seung Kim,et al. Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. , 2009, Bioconjugate chemistry.
[91] Weibo Cai,et al. Semiconductor quantum dots for in vivo imaging. , 2007, Journal of nanoscience and nanotechnology.
[92] Valery A. Petrenko,et al. Evolution of phage display: from bioactive peptides to bioselective nanomaterials , 2008 .
[93] Anna M Wu,et al. Antibodies for Molecular Imaging of Cancer , 2008, Cancer journal.
[94] V. Ntziachristos. Fluorescence molecular imaging. , 2006, Annual review of biomedical engineering.
[95] J. Xie,et al. Iron oxide nanoparticle platform for biomedical applications. , 2009, Current medicinal chemistry.
[96] Kaijun Zhang,et al. PET Imaging of VPAC1 Expression in Experimental and Spontaneous Prostate Cancer , 2007, Journal of Nuclear Medicine.
[97] Ick Chan Kwon,et al. Dark quenched matrix metalloproteinase fluorogenic probe for imaging osteoarthritis development in vivo. , 2008, Bioconjugate chemistry.
[98] Pius August Schubiger,et al. Molecular imaging with PET. , 2008, Chemical reviews.
[99] Matthias Glaser,et al. Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients , 2008, Journal of Nuclear Medicine.
[100] Ick Chan Kwon,et al. A new atherosclerotic lesion probe based on hydrophobically modified chitosan nanoparticles functionalized by the atherosclerotic plaque targeted peptides. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[101] Klaas Nicolay,et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[102] J C Reubi,et al. Unexpected high incidence of cholecystokinin‐B/gastrin receptors in human medullary thyroid carcinomas , 1996, International journal of cancer.
[103] Weibo Cai,et al. Nanoplatforms for targeted molecular imaging in living subjects. , 2007, Small.
[104] Martin Gotthardt,et al. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[105] Sanjiv S Gambhir,et al. Molecular imaging: the vision and opportunity for radiology in the future. , 2007, Radiology.
[106] J. Habener,et al. The glucagon-like peptides. , 1999, Endocrine reviews.
[107] Joseph A Frank,et al. Magnetic Tagging of Therapeutic Cells for MRI , 2009, Journal of Nuclear Medicine.
[108] Rex Moats,et al. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. , 2004, Nuclear medicine and biology.
[109] Patrick Pauwels,et al. Gastrin-Releasing Peptide Receptor Imaging in Human Breast Carcinoma Versus Immunohistochemistry , 2008, Journal of Nuclear Medicine.
[110] Young-Seung Kim,et al. Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. , 2008, Journal of medicinal chemistry.
[111] F Dumont,et al. Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[112] Shuming Nie,et al. Bioconjugated quantum dots for in vivo molecular and cellular imaging. , 2008, Advanced drug delivery reviews.
[113] C. Olbrich,et al. Optical imaging in drug discovery and diagnostic applications. , 2005, Advanced drug delivery reviews.
[114] A. Marcus,et al. Imaging and tracking of tat peptide-conjugated quantum dots in living cells: new insights into nanoparticle uptake, intracellular transport, and vesicle shedding. , 2007, Journal of the American Chemical Society.
[115] Jiqiu Chen,et al. Near-Infrared Fluorescent Imaging of Matrix Metalloproteinase Activity After Myocardial Infarction , 2005, Circulation.
[116] T. Hoffman,et al. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. , 2005, Nuclear medicine and biology.
[117] Markus Schwaiger,et al. [18F]Galacto-RGD Positron Emission Tomography for Imaging of αvβ3 Expression on the Neovasculature in Patients with Squamous Cell Carcinoma of the Head and Neck , 2007, Clinical Cancer Research.
[118] R. M. Cook,et al. Intramolecular dimers: a new design strategy for fluorescence-quenched probes. , 2003, Chemistry.
[119] Michael J. Welch,et al. Imaging of Melanoma Using 64Cu− and 86Y−DOTA−ReCCMSH(Arg11), a Cyclized Peptide Analogue of α-MSH , 2005 .
[120] Sibylle Ziegler,et al. Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .
[121] S. Jurisson,et al. In vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. , 1999, Nuclear medicine and biology.
[122] D. Cheresh,et al. Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.
[123] Sanjiv S. Gambhir,et al. How molecular imaging is speeding up antiangiogenic drug development , 2006, Molecular Cancer Therapeutics.
[124] M. Montminy,et al. Transcriptional regulation by cyclic AMP. , 1997, Annual review of biochemistry.
[125] K. Brown,et al. New approaches for cell-specific targeting: identification of cell-selective peptides from combinatorial libraries. , 2000, Current opinion in chemical biology.
[126] Erkki Ruoslahti,et al. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[127] Christian Bruns,et al. Opportunities in somatostatin research: biological, chemical and therapeutic aspects , 2003, Nature Reviews Drug Discovery.
[128] Kit S Lam,et al. From combinatorial chemistry to cancer-targeting peptides. , 2007, Molecular pharmaceutics.
[129] Veronique Maes,et al. Novel 99mTc-labeled neurotensin analogues with optimized biodistribution properties. , 2006, Journal of medicinal chemistry.
[130] E. D. de Vries,et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. , 2009, Critical reviews in oncology/hematology.
[131] Sanjiv S. Gambhir,et al. Near-Infrared Fluorescent RGD Peptides for Optical Imaging of Integrin αvβ3 Expression in Living Mice , 2005 .
[132] J C Reubi,et al. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. , 2000, Cancer research.
[133] D. Wong,et al. Translating an Antagonist of Chemokine Receptor CXCR4: From Bench to Bedside , 2008, Clinical Cancer Research.
[134] V. Hruby. Designing peptide receptor agonists and antagonists , 2002, Nature Reviews Drug Discovery.
[135] Donghoon Lee,et al. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. , 2008, Small.
[136] Zhuang Liu,et al. Carbon nanotubes as photoacoustic molecular imaging agents in living mice. , 2008, Nature nanotechnology.
[137] S. Deutscher,et al. Phage peptide display. , 2008, Handbook of experimental pharmacology.
[138] Seulki Lee,et al. Dual-Modality Probes for in Vivo Molecular Imaging , 2009, Molecular imaging.
[139] J. Habener,et al. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. , 1996, Endocrinology.
[140] Xianzhong Zhang,et al. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. , 2006, Nuclear medicine and biology.
[141] A. Schally,et al. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[142] Hariprasad Gali,et al. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[143] Z. Werb,et al. New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.